Ambu A/S (0MJF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Ambu A/S DKK 9.70, price DKK 67.63, upside -85.7%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ambu A/S for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 58.35 – kr 241.36 · fair‑value band kr 4.58 – kr 15.19 · the kr 67.63 price screens above the kr 9.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally.
Show more
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, as well as mobile workstations, IOMs, and patient monitoring and diagnostics devices. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
Stock analysis
Ambu A/S (0MJF) currently trades at kr 67.63, while our model-based Fair Value estimate is kr 9.70, 85.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 11.99 per share, and 0 of the 25 models we run sit above the kr 67.63 price.
Bear case: the Dividend Discount group reads lowest at kr 2.52, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 4.58 (bear) to kr 15.19 (bull), the price of kr 67.63 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ambu A/S reported revenue of 4.0B DKK in FY2021 versus 2.4B DKK in FY2017, a compound +14.3%/yr. Reported net income was 247M DKK in FY2021, compounding −4.8%/yr from FY2017.
Key figures
Market cap 30.4B DKK (≈ $4.6B) · P/E ratio 0.8 · P/S ratio 0.05 · EPS (TTM) kr 1.01 · Dividend yield 0.6% · Net margin 6.2% · Return on equity 7.9% · Return on assets (EBIT) 10.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −86%, 0MJF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 2.52 to kr 20.18). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 4.58Fair Value kr 9.70Bull kr 15.19
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.5%
’17
’18
’19
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
19.1% (2017) → 8.5% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−84.3% · Bottom 25%
Profitability
Return on equity (TTM)7.9% · Above median
Return on assets5.4% · Above median
Net margin (TTM)7.8% · Above median
Operating margin (TTM)11.0% · Above median
Growth and dividend
Revenue growth1.2% · Below median
Dividend yield (TTM)0.6% · Bottom 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ambu A/S Fair Value". https://www.fairvalue-calculator.com/stock/0MJF
Frequently asked questions
Is Ambu A/S (0MJF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 9.70 versus a price of kr 67.63, about −86% upside (overvalued).
What is the fair value of 0MJF?
Our model-based fair value for Ambu A/S is kr 9.70 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 67.63.
What is the quality score of 0MJF?
Ambu A/S has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ambu A/S (0MJF)?
Our model-based price target is the fair value of kr 9.70 (as of Sep 24, 2026) from 25 valuation models. Cautious scenario kr 4.58, optimistic scenario kr 15.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Ambu A/S stock forecast for 2026?
Our models put fair value at kr 9.70, about −86% upside versus a price of kr 67.63 (overvalued). Cautious scenario kr 4.58, optimistic scenario kr 15.19. The calculation is refreshed regularly with new filings.
What is the revenue of Ambu A/S (0MJF)?
Ambu A/S reported trailing-twelve-month revenue of about 6.1B DKK (latest available figure, as of Sep 24, 2026).
Does Ambu A/S pay a dividend?
Ambu A/S currently shows a dividend yield of about 0.61% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Ambu A/S (0MJF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ambu A/S it is kr 9.70 per share (as of Sep 24, 2026), against a price of kr 67.63. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Ambu A/S stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0MJF trades above its calculated fair value: price kr 67.63, fair value kr 9.70, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0MJF?
No. The price is what the market pays today (kr 67.63); the fair value is what the company's own numbers justify (kr 9.70). For Ambu A/S the two are kr 57.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ambu A/S worth?
The market values Ambu A/S at about 30.4B DKK (market capitalisation, as of Sep 24, 2026). Per share that is kr 67.63; our models calculate a fair value of kr 9.70 per share.
What do the bullish and bearish scenarios say about 0MJF?
Our models span a range for Ambu A/S: cautious scenario kr 4.58, base kr 9.70, optimistic kr 15.19 per share (as of Sep 24, 2026, price kr 67.63). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0MJF?
Ambu A/S trades at a price-to-earnings ratio of 0.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 9.70 is built from several models across several years.
How solid is the balance sheet of Ambu A/S (0MJF)?
Balance-sheet figures for Ambu A/S (as of Sep 24, 2026): return on equity 7.9%, debt of 0.14 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 0MJF from its 52-week high?
Ambu A/S trades at kr 67.63, about 38% below its 52-week high of kr 108.28 and 16% above the low of kr 58.35 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 9.70 is for.
Which stocks are comparable to Ambu A/S?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ambu A/S stock attractive at the current price?
The data as of Sep 24, 2026: price kr 67.63, calculated fair value kr 9.70 (−86%), Quality Score 51/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0MJF calculated?
We run Ambu A/S through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 9.70, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ambu A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ambu A/S (0MJF)?
The closing price on Oct 2, 2026 was kr 67.63. Our model-based fair value is kr 9.70, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ambu A/S right now?
The price sits above even our optimistic bull case (kr 15.19). The favourable scenario is already priced in. The model range is unusually wide (kr 4.58 to kr 15.19). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Ambu A/S
How large is the market capitalisation of Ambu A/S (0MJF)?
The market capitalisation of Ambu A/S is 30.4B DKK (≈ $4.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ambu A/S (0MJF)?
The price-to-sales ratio of Ambu A/S is 0.05 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ambu A/S (0MJF)?
Earnings per share at Ambu A/S are kr 1.01 (price ÷ EPS = P/E 0.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ambu A/S (0MJF)?
The dividend yield of Ambu A/S is 0.6% (payout 40.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ambu A/S (0MJF)?
The net margin of Ambu A/S is 6.2% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ambu A/S (0MJF)?
The return on equity (ROE) of Ambu A/S is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ambu A/S (0MJF)?
On an EBIT basis the return on assets of Ambu A/S is 10.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ambu A/S (0MJF)?
The operating margin of Ambu A/S is 11.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ambu A/S (0MJF)?
Revenue at Ambu A/S is growing +1.2% versus a year earlier (3y avg +15.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ambu A/S (0MJF)?
Earnings per share at Ambu A/S are growing −35.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Ambu A/S in the live analysis
One click puts Ambu A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
